retatrutide triple agonist obesity phase 2 trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ retatrutide triple agonist glp-1 gip

Like whether it treats GLP-1s as just another generic molecule or as a once-in-a-generation opportunity to build a full-stack industry that can handle molecules, devices, and cold chains together

Since diabetes and obesity are closely linked, we soon discovered that GLP-1 drugs not only controlled blood sugar but also promoted significant weight loss

Focus on soft, easily digestible foods initially, then gradually add soluble fiber sources like oatmeal and cooked vegetables

That makes it the most cost-effective vial size for most researchers

Vyrovnvaj hladinu cukru a energie: navrhnut tak, aby pomhali minimalizova vkyvy energie a udrali ju v stlej hladine